Mobile website
Volume 3,Issue 1,1996 Table of Contents
Shen Feng
,
Wu Mengchao
,
Chen Han
,
Xie Tianpei
,
Wang Hao
,
Cui Zhenfu
,
Shi Lehua
,
Qian Huizhu
,
Guo Yajun
1996, 3(1):6-5.
DOI: 10.3872/j.issn.1007-385X.1996.1.002
Abstract:
为研究NK细胞表面分子在NK细胞激活及释放细胞因子中的作用及其机制,作者用系列粘附分子单抗、配体及基因转染细胞刺激或共刺激NK细胞,定量检测IFN-γ的分泌。结果表明,CD45分子交联可独立激活NK细胞,CD45分子的信号传递作用对CD16分子无依赖性。随着NK细胞的成熟与分化,其表面CD45分子的表达呈现RA向RO变化的特征,而RO的交联,对NK细胞的刺激显著强于RA的交联。CD22α和CD22β基因转染细胞能显著粘附NK细胞系NK3.3(RO~+),但并不能有效刺激其产生IFN-γ。作者推测,CD45分子,尤其是CD45RO,是NK细胞表面独特的信号传递分子,通过直接激活Src家族的PTK成员,开启独立的、非CD16分子参与的NK细胞内信号传递途径。
为研究NK细胞表面分子在NK细胞激活及释放细胞因子中的作用及其机制,作者用系列粘附分子单抗、配体及基因转染细胞刺激或共刺激NK细胞,定量检测IFN-γ的分泌。结果表明,CD45分子交联可独立激活NK细胞,CD45分子的信号传递作用对CD16分子无依赖性。随着NK细胞的成熟与分化,其表面CD45分子的表达呈现RA向RO变化的特征,而RO的交联,对NK细胞的刺激显著强于RA的交联。CD22α和CD22β基因转染细胞能显著粘附NK细胞系NK3.3(RO~+),但并不能有效刺激其产生IFN-γ。作者推测,CD45分子,尤其是CD45RO,是NK细胞表面独特的信号传递分子,通过直接激活Src家族的PTK成员,开启独立的、非CD16分子参与的NK细胞内信号传递途径。
1996, 3(1):11-64.
DOI: 10.3872/j.issn.1007-385X.1996.1.003
Abstract:
The p53 gene is one of the most common targets for genetic abnormalities in human tumors. Restoring wild - type p53 gene (wt-p53) into cancer cells which have p53 deletion is a strategy in cancer gene therapy. In order to explore the feasibility of this hypothesis, we selected a gastric cancer cell line BGC823 which was confirmed having deletion of chromosome 17pl3 and decreased expression level of p53 mRNA . We transfected construct pC53SN3 containing wt - p53 into BGC823 cell line with lipofectin mediated gene transferration, and G418 resistant colonies were characterized by using analysis of PCR, Southern blot hybridization, Northern blot hybridization and Western blot hybridization. These data showed that exogenous wt-p53 had successfully transferred into BGC823 cells and obtained high expression. The cell growth rates in regular medium and soft agar were inhibited from 30 to 40 percent in the BGC823 cells transfected with wt - p53. The tumorigenicity in nude mice showed that one of four mice failed to form tumor and three of them delayed to form tumor from 7 to 14 days comparing with monk and parent BGC823 cells. These results suggested that exogenous wt -p53 could suppress the growth ability and tumorigenicity of human gastric cancer cells. The method of using lipofectin mediated wt-p53 gene transfection may have a potentially therapeutic effect on human gastric cancer.
The p53 gene is one of the most common targets for genetic abnormalities in human tumors. Restoring wild - type p53 gene (wt-p53) into cancer cells which have p53 deletion is a strategy in cancer gene therapy. In order to explore the feasibility of this hypothesis, we selected a gastric cancer cell line BGC823 which was confirmed having deletion of chromosome 17pl3 and decreased expression level of p53 mRNA . We transfected construct pC53SN3 containing wt - p53 into BGC823 cell line with lipofectin mediated gene transferration, and G418 resistant colonies were characterized by using analysis of PCR, Southern blot hybridization, Northern blot hybridization and Western blot hybridization. These data showed that exogenous wt-p53 had successfully transferred into BGC823 cells and obtained high expression. The cell growth rates in regular medium and soft agar were inhibited from 30 to 40 percent in the BGC823 cells transfected with wt - p53. The tumorigenicity in nude mice showed that one of four mice failed to form tumor and three of them delayed to form tumor from 7 to 14 days comparing with monk and parent BGC823 cells. These results suggested that exogenous wt -p53 could suppress the growth ability and tumorigenicity of human gastric cancer cells. The method of using lipofectin mediated wt-p53 gene transfection may have a potentially therapeutic effect on human gastric cancer.
Guo Ning
,
Li Xiusen
,
Liu Xiaodan
,
Zhang Mingwei
,
Du Delin
,
Mao Ning
,
Tu Kaicheng
,
Cao Zhenshan
1996, 3(1):21-25.
DOI: 10.3872/j.issn.1007-385X.1996.1.005
Abstract:
IL-2 gene was introduced into human erythroleukemic cell line K562 by retroviral vector. After transduction for eighteen days, flow microfluorometric analysis for DNA distribution of both K562/neo and K562/IL-2 cells indicated that transduced cells were accumulated in a state of G2M arrest. Thirty days later, the number of G2 M in K562/neo cells decreased, but proportion of G0/G1 in K562/IL-2 cells was still lower and G2 M was higher than that of nontransduced cells. The proliferative activity assay by MTT method demonstrated that the proliferation of K562/IL-2 was slow following four day culture. The index of mitosis was decreased. The results of light microscopical studies showed many giant and multinucleate giant cells with even more than twenty nuclei in each cell. It was possible that the formation of multinucleate giant cells associated with repeated endomitosis in a single cell. Further analysis of morphometry confirmed that the size of IL-2 gene modified K562 cells was increased. The ratio of giant cells was higher than that of nontransduced K562 cells. We suggested that I1-2 gene transduction might have some regulation effects on proliferative activity of K562 cells. IL-2 gene modified K562 cells might be blocked at a stage of G2.
IL-2 gene was introduced into human erythroleukemic cell line K562 by retroviral vector. After transduction for eighteen days, flow microfluorometric analysis for DNA distribution of both K562/neo and K562/IL-2 cells indicated that transduced cells were accumulated in a state of G2M arrest. Thirty days later, the number of G2 M in K562/neo cells decreased, but proportion of G0/G1 in K562/IL-2 cells was still lower and G2 M was higher than that of nontransduced cells. The proliferative activity assay by MTT method demonstrated that the proliferation of K562/IL-2 was slow following four day culture. The index of mitosis was decreased. The results of light microscopical studies showed many giant and multinucleate giant cells with even more than twenty nuclei in each cell. It was possible that the formation of multinucleate giant cells associated with repeated endomitosis in a single cell. Further analysis of morphometry confirmed that the size of IL-2 gene modified K562 cells was increased. The ratio of giant cells was higher than that of nontransduced K562 cells. We suggested that I1-2 gene transduction might have some regulation effects on proliferative activity of K562 cells. IL-2 gene modified K562 cells might be blocked at a stage of G2.
4 hG-CSF cDNA Cloning and the Construction and Applicaltion in Gene Therapy of Its Retroviral Vector
1996, 3(1):26-32.
DOI: 10.3872/j.issn.1007-385X.1996.1.006
Abstract:
利用RT-PCR方法克隆到包括有全部编码序列和部分5′、3′端非编码序列的人G-CSF cDNA,并通过核苷酸测序得到证实。将其定向克隆至逆转录病毒载体pLXSN,构建成人G-CSF的重组逆转录病毒表达载体pLGSN。体外经CRE和CRIP细胞的两次包装,病毒滴度达到了临床应用的水平(1.1×10~6CFU/ml)。hG-CSF逆转录病毒感染NIH3T3小鼠成纤维细胞后,分泌G-CSF达168U/ml,Southern分析表明hG-CSF基因已整合至NIH3T3-G-CSF细胞的基因组中,Northern和Western分析分别从mRNA和蛋白质水平证实了人G-CSF在NIH3T3-G-CSF细胞的表达。将NIH3T3-G-CSF细胞植入同系小鼠体内,能从血清中检测到持续表达的G-CSF活性。本研究为开展人G-CSF基因治疗奠定了基础。
利用RT-PCR方法克隆到包括有全部编码序列和部分5′、3′端非编码序列的人G-CSF cDNA,并通过核苷酸测序得到证实。将其定向克隆至逆转录病毒载体pLXSN,构建成人G-CSF的重组逆转录病毒表达载体pLGSN。体外经CRE和CRIP细胞的两次包装,病毒滴度达到了临床应用的水平(1.1×10~6CFU/ml)。hG-CSF逆转录病毒感染NIH3T3小鼠成纤维细胞后,分泌G-CSF达168U/ml,Southern分析表明hG-CSF基因已整合至NIH3T3-G-CSF细胞的基因组中,Northern和Western分析分别从mRNA和蛋白质水平证实了人G-CSF在NIH3T3-G-CSF细胞的表达。将NIH3T3-G-CSF细胞植入同系小鼠体内,能从血清中检测到持续表达的G-CSF活性。本研究为开展人G-CSF基因治疗奠定了基础。
1996, 3(1):33-37.
DOI: 10.3872/j.issn.1007-385X.1996.1.007
Abstract:
In the present study, the effects of G-CSF gene therapy was investigated on the recovery of murine hematopoietic suppression induced by high dose of cyclophosphomide (Cy) . The results showed that G-CSF gene therapy could slow down the Cy-induced decreasing of peripheral WBCs and platelets, and accerelate their recovery.It also could increase the CFU-GM, CFU - MK, CFU-S derived from the splenocyte and bone marrow cells in the chemotherapy-treated mice. The data demonstrated that fibroblast-mediated G-CSF gene therapy could significantlyreduce the hematopoietic damage to less extent, and accerelate hematopoietic recovery after chemotherapy.
In the present study, the effects of G-CSF gene therapy was investigated on the recovery of murine hematopoietic suppression induced by high dose of cyclophosphomide (Cy) . The results showed that G-CSF gene therapy could slow down the Cy-induced decreasing of peripheral WBCs and platelets, and accerelate their recovery.It also could increase the CFU-GM, CFU - MK, CFU-S derived from the splenocyte and bone marrow cells in the chemotherapy-treated mice. The data demonstrated that fibroblast-mediated G-CSF gene therapy could significantlyreduce the hematopoietic damage to less extent, and accerelate hematopoietic recovery after chemotherapy.
1996, 3(1):38-64.
DOI: 10.3872/j.issn.1007-385X.1996.1.008
Abstract:
The Renca-bearing mice were treated by combined fibroblast-mediated IL-2 and G-CSF gene therapy. The survival periods of Renca-bearing mice were prolonged markedly and 75% of Renca-bearing mice were cured. The spleens of Renca-bearing mice treated by fibroblast-mediated G-CSF gene therapy were larger than the spleens of other mice. Histologic analysis of tumor showed that there were a number of infiltrating eosinophils. The NK, LAK and CTL activity induced from the splenocytes of the tumor-bearing mice increased siginificantly when the mice were treated by fibroblast-mediated IL-2 gene therapy and the cytotoxicity of macrophages also increased. The results demonstrated that the and - tumor responses might be induced more significantly by combined fibroblast-mediated IL-2 and G-CSF gene therapy and better antitumor effect may be achieved.
The Renca-bearing mice were treated by combined fibroblast-mediated IL-2 and G-CSF gene therapy. The survival periods of Renca-bearing mice were prolonged markedly and 75% of Renca-bearing mice were cured. The spleens of Renca-bearing mice treated by fibroblast-mediated G-CSF gene therapy were larger than the spleens of other mice. Histologic analysis of tumor showed that there were a number of infiltrating eosinophils. The NK, LAK and CTL activity induced from the splenocytes of the tumor-bearing mice increased siginificantly when the mice were treated by fibroblast-mediated IL-2 gene therapy and the cytotoxicity of macrophages also increased. The results demonstrated that the and - tumor responses might be induced more significantly by combined fibroblast-mediated IL-2 and G-CSF gene therapy and better antitumor effect may be achieved.
1996, 3(1):42-44.
DOI: 10.3872/j.issn.1007-385X.1996.1.009
Abstract:
The Renca-bearing mice were treated by combined fibroblast-mediated IL-2 and G-CSF gene therapy. The survival periods of Renca-bearing mice were prolonged markedly and 75% of Renca-bearing mice were cured. The spleens of Renca-bearing mice treated by fibroblast-mediated G-CSF gene therapy were larger than the spleens of other mice. Histologic analysis of tumor showed that there were a number of infiltrating eosinophils. The NK, LAK and CTL activity induced from the splenocytes of the tumor-bearing mice increased siginificantly when the mice were treated by fibroblast-mediated IL-2 gene therapy and the cytotoxicity of macrophages also increased. The results demonstrated that the and - tumor responses might be induced more significantly by combined fibroblast-mediated IL-2 and G-CSF gene therapy and better antitumor effect may be achieved.
The Renca-bearing mice were treated by combined fibroblast-mediated IL-2 and G-CSF gene therapy. The survival periods of Renca-bearing mice were prolonged markedly and 75% of Renca-bearing mice were cured. The spleens of Renca-bearing mice treated by fibroblast-mediated G-CSF gene therapy were larger than the spleens of other mice. Histologic analysis of tumor showed that there were a number of infiltrating eosinophils. The NK, LAK and CTL activity induced from the splenocytes of the tumor-bearing mice increased siginificantly when the mice were treated by fibroblast-mediated IL-2 gene therapy and the cytotoxicity of macrophages also increased. The results demonstrated that the and - tumor responses might be induced more significantly by combined fibroblast-mediated IL-2 and G-CSF gene therapy and better antitumor effect may be achieved.
Chen Guoqiang
,
Guo Kunyuan
,
Wang Senming
,
Zhao Yan
,
Shen Shuhua
,
Wang Wei
,
Gu Peixia
,
Wang Bing
1996, 3(1):45-53.
DOI: 10.3872/j.issn.1007-385X.1996.1.010
Abstract:
We treated 8 patients with refractory non small cell lung cancer by the method of double - cycle high dose chemotherapy with actwated autologous bone marrow, peripheral stem cell, and immunocytes trnsplantation which takes four months. Regimen consist of cyclophospamide 3600mg/m2, adriamycin 90mg/m2 , cisplatin 150mg/m2, and etoposide 900mg/m2 given in three days. The results showed that all the treated patients hematopoietic function recovered in twenty five days after transplantation and some of the patients' immune function recovered more quickly. 3 patients were abtained complete responses , 3 patients partial responses, and 1 patient no change 1 patient died after the double cycle treatment. This research suggests that usage of high dose chemotherapy can improve the treating effect of refractory non small cell lung cancer. It is necessary for the patient with disease to use the double cycle transplantation treatment. The treatment is safe.
We treated 8 patients with refractory non small cell lung cancer by the method of double - cycle high dose chemotherapy with actwated autologous bone marrow, peripheral stem cell, and immunocytes trnsplantation which takes four months. Regimen consist of cyclophospamide 3600mg/m2, adriamycin 90mg/m2 , cisplatin 150mg/m2, and etoposide 900mg/m2 given in three days. The results showed that all the treated patients hematopoietic function recovered in twenty five days after transplantation and some of the patients' immune function recovered more quickly. 3 patients were abtained complete responses , 3 patients partial responses, and 1 patient no change 1 patient died after the double cycle treatment. This research suggests that usage of high dose chemotherapy can improve the treating effect of refractory non small cell lung cancer. It is necessary for the patient with disease to use the double cycle transplantation treatment. The treatment is safe.
1996, 3(1):48-50.
DOI: 10.3872/j.issn.1007-385X.1996.1.011
Abstract:
We compared the changes of c-myc expression, cell growth kinetics, ability to reduce NBT and 3H -TdR incorporation rate of HL-60 cells in low concentration of FCS, or treated by TNF or no treatment, respectively. The results showed that, although the prolifcrative suppression of HL-60 cells treated by 50U/ml TNF was mimicked by adding 1. 0%and 0. 5?S in culture media, the differentiation had notappeared and it had not effected on c - myc expression, either. TNF (50U/ml) could inhibit proliferation of HL-60 cells during inducing differentiation and the expression of c-myc oncogene decreased remarkedly. The results indicated that decreased expression of c-myc in TNF treated HL-60 cells were mainly connected with differentiate maturation but not with proliferative suppression.
We compared the changes of c-myc expression, cell growth kinetics, ability to reduce NBT and 3H -TdR incorporation rate of HL-60 cells in low concentration of FCS, or treated by TNF or no treatment, respectively. The results showed that, although the prolifcrative suppression of HL-60 cells treated by 50U/ml TNF was mimicked by adding 1. 0%and 0. 5?S in culture media, the differentiation had notappeared and it had not effected on c - myc expression, either. TNF (50U/ml) could inhibit proliferation of HL-60 cells during inducing differentiation and the expression of c-myc oncogene decreased remarkedly. The results indicated that decreased expression of c-myc in TNF treated HL-60 cells were mainly connected with differentiate maturation but not with proliferative suppression.
1996, 3(1):51-54.
DOI: 10.3872/j.issn.1007-385X.1996.1.012
Abstract:
The titer of Interleukin-2 (IL-2), prepared from the healthy human peripheral blood lymphoytes which were stimulating-induced by carboxymethy-parchymaran (CMP), was very high and reached clinical drug level after special process. The IL-2 was not only available for intramuscular injection. but also for intravenous in jection or even for intraarterial, injection 44 partients with advanced malignant tumor treated with the combination of IL-2 / LAK and chemotherapy showed an overall objective response rate to 86. 4% (CR PR: 13, 29.3%); (CR PR MR: 22, 50%); (CR PR MR SR : 38, 86. 4%) . 37 Patients with various malignant tumors were treated by low-dose interleukin-2 stinulated with CMP and irradiation with 60Co. The percentages of CR, PR and SR were 51.4%, 46.8%and 2.7%, respectively. Overall effectiveness rate was 97.3%. 1 year survival rate was 86.2%. 16 Patients with various advanced cancers were treated by low-dose interleukin-2 stimulated with CMP and low - dose radiotherapy or chemotherapy. The percentage of CR, PR and SR was 37. 5%, 56. 3%and 6 . 3%, respectively. Overall effective rate was 93. 8%. 1 year survival rate was 87. 5%. The current results indicate that the possibility of combined therapy of the low - dose IL-2/LAK adoptive chemoimmunotherapy and radiotherapy or chemotherapy may be effective in treatment of advanced cancer.
The titer of Interleukin-2 (IL-2), prepared from the healthy human peripheral blood lymphoytes which were stimulating-induced by carboxymethy-parchymaran (CMP), was very high and reached clinical drug level after special process. The IL-2 was not only available for intramuscular injection. but also for intravenous in jection or even for intraarterial, injection 44 partients with advanced malignant tumor treated with the combination of IL-2 / LAK and chemotherapy showed an overall objective response rate to 86. 4% (CR PR: 13, 29.3%); (CR PR MR: 22, 50%); (CR PR MR SR : 38, 86. 4%) . 37 Patients with various malignant tumors were treated by low-dose interleukin-2 stinulated with CMP and irradiation with 60Co. The percentages of CR, PR and SR were 51.4%, 46.8%and 2.7%, respectively. Overall effectiveness rate was 97.3%. 1 year survival rate was 86.2%. 16 Patients with various advanced cancers were treated by low-dose interleukin-2 stimulated with CMP and low - dose radiotherapy or chemotherapy. The percentage of CR, PR and SR was 37. 5%, 56. 3%and 6 . 3%, respectively. Overall effective rate was 93. 8%. 1 year survival rate was 87. 5%. The current results indicate that the possibility of combined therapy of the low - dose IL-2/LAK adoptive chemoimmunotherapy and radiotherapy or chemotherapy may be effective in treatment of advanced cancer.
1996, 3(1):55-56.
DOI: 10.3872/j.issn.1007-385X.1996.1.013
Abstract:
The titer of Interleukin-2 (IL-2), prepared from the healthy human peripheral blood lymphoytes which were stimulating-induced by carboxymethy-parchymaran (CMP), was very high and reached clinical drug level after special process. The IL-2 was not only available for intramuscular injection. but also for intravenous in jection or even for intraarterial, injection 44 partients with advanced malignant tumor treated with the combination of IL-2 / LAK and chemotherapy showed an overall objective response rate to 86. 4% (CR PR: 13, 29.3%); (CR PR MR: 22, 50%); (CR PR MR SR : 38, 86. 4%) . 37 Patients with various malignant tumors were treated by low-dose interleukin-2 stinulated with CMP and irradiation with 60Co. The percentages of CR, PR and SR were 51.4%, 46.8%and 2.7%, respectively. Overall effectiveness rate was 97.3%. 1 year survival rate was 86.2%. 16 Patients with various advanced cancers were treated by low-dose interleukin-2 stimulated with CMP and low - dose radiotherapy or chemotherapy. The percentage of CR, PR and SR was 37. 5%, 56. 3%and 6 . 3%, respectively. Overall effective rate was 93. 8%. 1 year survival rate was 87. 5%. The current results indicate that the possibility of combined therapy of the low - dose IL-2/LAK adoptive chemoimmunotherapy and radiotherapy or chemotherapy may be effective in treatment of advanced cancer.
The titer of Interleukin-2 (IL-2), prepared from the healthy human peripheral blood lymphoytes which were stimulating-induced by carboxymethy-parchymaran (CMP), was very high and reached clinical drug level after special process. The IL-2 was not only available for intramuscular injection. but also for intravenous in jection or even for intraarterial, injection 44 partients with advanced malignant tumor treated with the combination of IL-2 / LAK and chemotherapy showed an overall objective response rate to 86. 4% (CR PR: 13, 29.3%); (CR PR MR: 22, 50%); (CR PR MR SR : 38, 86. 4%) . 37 Patients with various malignant tumors were treated by low-dose interleukin-2 stinulated with CMP and irradiation with 60Co. The percentages of CR, PR and SR were 51.4%, 46.8%and 2.7%, respectively. Overall effectiveness rate was 97.3%. 1 year survival rate was 86.2%. 16 Patients with various advanced cancers were treated by low-dose interleukin-2 stimulated with CMP and low - dose radiotherapy or chemotherapy. The percentage of CR, PR and SR was 37. 5%, 56. 3%and 6 . 3%, respectively. Overall effective rate was 93. 8%. 1 year survival rate was 87. 5%. The current results indicate that the possibility of combined therapy of the low - dose IL-2/LAK adoptive chemoimmunotherapy and radiotherapy or chemotherapy may be effective in treatment of advanced cancer.
联系方式
- 《中国肿瘤生物治疗杂志》
- 1994年创刊
- 主办单位：Chinese Society of Immunology, Chinese Anti-cancer Association
- 邮编：200433
- 电话：021-81871002-22
- 电子邮箱：cjcb@biother.cn
- 网址:http://www.biother.cn
- 刊号：ISSN 1007-385X
- CN 31-1725/R
- 国内定价： ￥20元/册
您是第位访问者
Chinese Journal Of Cancer Biotheray ® 2025 All Rights Reserved
Supported by:Beijing E-Tiller Technology Development Co., Ltd.
Chinese Journal Of Cancer Biotheray ® 2025 All Rights Reserved
Supported by:Beijing E-Tiller Technology Development Co., Ltd.